Evidence map›Paper›PMID 41779447›Full record

ArticleJournal of the American Society of Nephrology : JASN2026

Systemic Proteome Profiling to Differentiate Primary Glomerular Diseases.

Jae-Ik Oh, Kyeonghun Jeong, Jung Hun Koh, Jin Kyung Kwon, Semin Cho, Jeong Min Cho, Yaerim Kim, Hajeong Lee, Hyun Je Kim, Jeonghwan Lee and 7 more

Abstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jae-Ik OhDepartment of Translational Medicine, Seoul National University College of Medicine, Seoul, South Korea.ORCID 0009-0001-7497-1067
Kyeonghun JeongDepartment of Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, South Korea.ORCID 0000-0001-8265-1576
Jung Hun KohDepartment of Translational Medicine, Seoul National University College of Medicine, Seoul, South Korea.ORCID 0000-0001-7373-5487
Jin Kyung KwonDepartment of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, South Korea.ORCID 0009-0000-3986-0639
Semin ChoDepartment of Translational Medicine, Seoul National University College of Medicine, Seoul, South Korea.ORCID 0000-0002-6060-9032
Jeong Min ChoDepartment of Translational Medicine, Seoul National University College of Medicine, Seoul, South Korea.ORCID 0000-0001-7643-994
Yaerim KimDepartment of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, South Korea.ORCID 0000-0003-1596-1528
Hajeong LeeDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.ORCID 0000-0002-1873-1587
Hyun Je KimDepartment of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea.ORCID 0000-0002-4184-6702
Jeonghwan LeeDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.ORCID 0000-0003-3199-635
Jung Pyo LeeDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.ORCID 0000-0002-4714-1260
Ji In ParkDepartment of Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, South Korea.ORCID 0000-0003-4662-3759
Jung Tak ParkDepartment of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, South Korea.ORCID 0000-0002-2325-8982
Kwangsoo KimDepartment of Transdisciplinary Medicine, Institute of Convergence Medicine with Innovative Technology, Seoul National University Hospital, Seoul, South Korea.ORCID 0000-0002-4586-5062
Sehoon ParkDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.ORCID 0000-0002-4221-2453
Dong Ki KimDepartment of Translational Medicine, Seoul National University College of Medicine, Seoul, South Korea.ORCID 0000-0002-5195-7852
KORNERSTONE Investigators

Funding

Ministry of Health and Welfare RS-2024-00403375Ministry of Health and Welfare RS-2024-00403492Ministry of Health and Welfare RS-2025-25459535National Research Foundation of Korea RS-2024-00345867
6 · The paper itself

Abstract

key pointsPlasma proteome profiling identified distinct signatures across biopsy-proven primary glomerular disease subtypes. An elastic net model using 93 proteins classified primary glomerular disease subtypes and controls, with external validation. Integrating proteomics with machine learning yields biologically interpretable insights in primary glomerular diseases.

backgroundPrimary GN is a heterogeneous group of kidney disorders where understanding of their pathophysiology remains incomplete. Despite the diagnostic potential of high-throughput proteomics, constrained proteomic depth and a reliance on binary comparisons have left the feasibility of using systemic signatures to differentiate multiple GN subtypes largely unexplored.

methodsTo identify protein signatures that noninvasively differentiate major primary glomerular disease subtypes and provide mechanistic insights, we performed large-scale systemic proteome profiling of 5416 plasma proteins via Olink Explore HT in a discovery cohort ( n =147) and an external validation cohort ( n =85) of Korean participants (mean age, 41±13 years; 46% female). The study population included patients with four GN subtypes-focal segmental glomerulosclerosis, IgA nephropathy, minimal change disease, and membranous nephropathy-alongside healthy controls. We developed a machine learning (ML) model using logistic regression with elastic net regularization to classify disease groups based on proteomic profiles and evaluated its performance in the independent validation cohort.

resultsPlasma proteome profiles were distinct among disease subtypes, emerging as a significant source of data variation independent of conventional markers such as eGFR or proteinuria levels. The ML model performed robustly in both the discovery and validation cohorts, achieving an area under the receiver operating characteristic curve >0.8 for differentiating minimal change disease, membranous nephropathy, and IgA nephropathy. The model, even without clinical information, correctly identified 93% of minimal change disease cases (14 of 15) and 63% of IgA nephropathy cases (20 of 32), but its performance was limited for focal segmental glomerulosclerosis, with only 21% of cases (three of 14) correctly classified. Functional analysis of key proteins highlighted distinct biologic pathways, such as hemostasis in minimal change disease.

conclusionsWe identified distinct systemic proteome signatures for primary glomerular diseases, where disease subtype served as a major determinant of proteomic variance alongside conventional clinical markers. ML models demonstrated robust discriminatory performance for minimal change disease, membranous nephropathy, and IgA nephropathy, underscoring the potential for proteome-based classification.

Indexed as

GlomerulonephritisGlomerulonephritis, IGAGlomerulonephritis, MembranousNephrosis, LipoidProteomeProteomicsAdultBlood ProteinsDiagnosis, DifferentialFemaleGlomerulosclerosis, Focal SegmentalHumansMachine LearningMaleMiddle AgedBlood ProteinsProteomebiomarkersprimary GNproteomics

Identifiers

PMID41779447
PMCPMC13567898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.